Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.00K | 5.60K | -- | -1.60K | -3.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.00K | 5.60K | -- | -1.60K | -3.20K |
| Cost of Revenue | 18.40K | 12.30K | 6.00K | 6.80K | 7.70K |
| Gross Profit | -7.40K | -6.70K | -6.00K | -8.40K | -10.90K |
| SG&A Expenses | 3.53M | 3.99M | 4.44M | 4.24M | 4.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.06M | 28.32M | 42.61M | 46.81M | 51.22M |
| Operating Income | -14.05M | -28.32M | -42.61M | -46.81M | -51.22M |
| Income Before Tax | -10.30M | -24.67M | -39.06M | -42.56M | -46.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.30 | -24.67 | -39.06 | -42.56 | -46.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.30M | -24.67M | -39.06M | -42.56M | -46.22M |
| EBIT | -14.05M | -28.32M | -42.61M | -46.81M | -51.22M |
| EBITDA | -13.95M | -28.22M | -42.51M | -46.71M | -51.13M |
| EPS Basic | -0.03 | -0.08 | -0.13 | -0.15 | -0.17 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.08 | -0.09 | -0.10 |
| EPS Diluted | -0.03 | -0.08 | -0.13 | -0.15 | -0.17 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.08 | -0.09 | -0.10 |
| Average Basic Shares Outstanding | 1.28B | 1.23B | 1.17B | 1.12B | 1.06B |
| Average Diluted Shares Outstanding | 1.28B | 1.23B | 1.17B | 1.12B | 1.06B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |